Haemophilia Treatment Market Growth Analysis Report - Market Size, Share, Forecast Trends and Outlook (2026-2035)

Haemophilia Treatment Market Overview

Haemophilia is a rare inherited bleeding disorder in which the blood does not clot properly due to the absence or deficiency of clotting factors, typically factor VIII or IX. This condition leads to prolonged bleeding, spontaneous haemorrhages, and joint or muscle damage if untreated. Haemophilia is more common in males and is often diagnosed in early childhood. Treatment involves regular replacement therapy using clotting factor concentrates, either plasma-derived or recombinant. Newer therapies, including gene therapy and extended half-life factors, aim to reduce bleeding episodes, improve quality of life, and offer more convenient treatment regimens.

Haemophilia Treatment Market Growth Drivers

Innovative Prophylactic Therapies to Strengthen Market Growth

Advances in targeted therapies and rising preference for effective prophylactic treatments are significantly propelling the market. For instance, in March  2025, the US FDA approved Qfitlia (fitusiran), a first-in-class antithrombin-lowering therapy designed to prevent or reduce bleeding episodes in haemophilia A or B patients with or without inhibitors, aged 12 years or older. Based on ATLAS Phase 3 trial data, it demonstrated meaningful bleed protection across diverse haemophilia populations. This approval is expected to boost market expansion by offering a new, efficient treatment pathway and attracting investment in prophylactic research and development.

Emphasis on Gene Therapies to Drive Haemophilia Treatment Market Value

Gene therapy advancements and a rising demand for long-acting, durable solutions continue to shape the market landscape. For instance, in February  2025, CSL presented four-year data from its HOPE-B study on HEMGENIX® (etranacogene dezaparvovec-drlb), which confirmed the long-term safety and effectiveness of this single-infusion gene therapy for adults with haemophilia B. The results, shared at the 18th EAHAD Congress, highlighted sustained factor IX levels, reduced bleeding episodes, and elimination of routine prophylaxis. This news strengthens confidence in gene therapy's transformative role, likely accelerating its adoption, broadening eligible patient access, and positively influencing global market growth.

Haemophilia Treatment Market Trends

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Haemophilia Treatment Market Segmentation

Haemophilia Treatment Market Share

Haemophilia A to Lead the Disease Type Segment 

Haemophilia A is projected to hold the largest market share by disease type, primarily due to its higher prevalence compared to other types. Increased awareness, genetic screening, and diagnosis have contributed to early identification and management. The Centers for Disease Control and Prevention (CDC) estimates revealed that nearly 12 in 100,000 males are affected by the genetic disorder in the United States. Additionally, there are around 400 newborn males each year born with Haemophilia A in the United States.  Market expansion is further driven by ongoing research and a strong pipeline of factor VIII therapies. Government support and improved healthcare access in developing regions are also boosting this segment. Continuous innovations, including gene therapy and long-acting recombinant factors, make Haemophilia A treatments more sustainable, positioning this segment as the key driver of future market value and development.

Replacement Therapy to Lead the Share by Treatment Type

Replacement therapy is expected to dominate the market share by treatment type, owing to its established clinical efficacy and widespread adoption. It directly addresses clotting factor deficiency, reducing the frequency and severity of bleeding episodes. Technological advancements in recombinant products and prophylactic regimens are improving patient outcomes, boosting market uptake. The growing availability of long-acting factors and increasing patient compliance support sustained growth. This segment benefits from increasing R&D investments and favourable reimbursement policies, making it central to the treatment paradigm and a major contributor to rising market demand and therapeutic innovation.

Adults Segment to Dominate the Haemophilia Treatment Market Segmentation by Patient 

The adult patient segment is poised to lead the market by patient type, due to the cumulative burden of haemophilia and the need for long-term management. Many adults experience complications such as joint damage, which necessitate ongoing treatment, increasing the market value. Additionally, rising diagnosis rates in adulthood and greater access to advanced therapies enhance this segment’s dominance. Expanding adult patient registries and growing awareness campaigns are also contributing to improved healthcare engagement. The adult population is more likely to seek regular care, which drives consistent market demand and supports the long-term development of treatment solutions.

Intravenous Route Dominating the Haemophilia Treatment Market by Route of Administration

The intravenous route of administration remains the leading segment due to its reliability in delivering factor replacement and bypassing agents directly into the bloodstream. This method ensures rapid therapeutic action, especially during acute bleeding episodes. Its dominance is supported by its longstanding clinical use and compatibility with both on-demand and prophylactic therapies. While newer methods like subcutaneous delivery are emerging, intravenous administration continues to be the gold standard, particularly in severe cases. Robust clinical data, patient familiarity, and integration into home treatment regimens position this segment as a stable and growing contributor to overall market expansion.

Hospitals to Lead the Haemophilia Treatment Market Share by End User

Hospitals are expected to maintain their position as the dominant end user in the market, driven by the need for advanced medical supervision and infusion capabilities. These settings are essential for initiating treatment, managing severe cases, and conducting gene therapy. The presence of specialist haematology units and access to multidisciplinary care also enhance treatment outcomes. Inpatient services remain critical for acute and surgical interventions. With increasing hospital-based care in developing markets and continuous infrastructure improvements, this segment is projected to experience steady growth, reinforcing its central role in market development and healthcare delivery.

Purchase the Regional Overview for USD 1099

If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.

Purchase the Regional Overview for USD 1099

If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.

Purchase the Regional Overview for USD 1099

If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.

Haemophilia Treatment Market Analysis by Region

The United States is likely to retain the largest market share owing to its early adoption of gene therapies, robust insurance coverage, and the strong presence of biopharmaceutical innovators. High diagnosis rates and extensive clinical trials fuel market maturity. Germany and France are rapidly expanding due to structured haemophilia registries and government-backed reimbursement schemes. The United Kingdom’s NHS initiatives support equitable access. Meanwhile, Japan sees steady growth through strategic biosimilar use, and India is witnessing gradual market penetration via global NGO support. Italy and Spain show modest expansion, primarily in recombinant therapies. However, the U.S. continues to lead due to its advanced infrastructure and treatment innovation pipeline.

Leading Players in the Haemophilia Treatment Market

Key Questions Answered in the Haemophilia Treatment Market

• What was the haemophilia treatment market value in 2025? 
• What is the haemophilia treatment market forecast outlook for 2026-2035?
• What is market segmentation based on disease type?
• What is market segmentation based on treatment type?
• What is market segmentation based on patient?
• What is market segmentation based on route of administration?
• What is market segmentation based on end users?
• What are the major factors aiding the haemophilia treatment market demand?  
• How has the market performed so far, and how is it anticipated to perform in the coming years? 
• What are the market's major drivers, opportunities, and restraints?
• What are the major haemophilia treatment market trends?
• Which disease type will lead the market segment?  
• Which treatment type will lead the market segment?  
• Which patient will lead the market segment?  
• Which route of administration will lead the market segment?  
• Which end user will lead the market segment?  
• Who are the key players involved in the haemophilia treatment market? 
• What is the patent landscape of the market? 
• What are the current unmet needs and challenges in the market?
• How are partnerships, collaborations, mergers, and acquisitions among the key market players shaping the market dynamics?

Haemophilia Treatment Market Report Snapshots

Haemophilia Treatment Companies